Comprehensive Analysis of U.S. Patent 6,572,873: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,572,873, granted on June 10, 2003, represents a significant patent in the pharmaceutical landscape, particularly in the context of targeted drug delivery and therapeutic agents. This patent covers specific formulations and methods related to drug compounds, with primary claims focused on novel pharmaceutical compositions and their use. Analyzing the scope and claims reveals the patent's breadth, potential overlaps with related patents, and its influence on subsequent innovations. This report synthesizes the patent's claims, structure, and the landscape of related intellectual property, highlighting critical insights for innovators, legal professionals, and industry stakeholders.
1. Overview of U.S. Patent 6,572,873
Inventors: Robert J. Hsueh et al.
Assignee: Schering Corporation (subsidiary of Merck & Co.)
Filing Date: December 18, 1998
Grant Date: June 10, 2003
Title: Methods for Treating Patients Using Potassium-Competitive Acid Blockers or Composition Thereof
This patent primarily describes a class of potassium-competitive acid blockers (P-CABs), used for gastric acid suppression, crucial in treating conditions like GERD, Zollinger-Ellison syndrome, and peptic ulcers.
2. Patent Scope and Core Claims
Scope Overview:
The patent’s scope is centered around specific chemical entities, pharmaceutical compositions containing these compounds, and methods of use for acid-related disorders. The inventive aspect focuses on novel P-CAB compounds that offer advantages over prior art, such as improved potency, selectivity, and pharmacokinetic profiles.
3. Key Claims Breakdown
Below is a detailed table summarizing the primary independent claims, their scope, and dependent claims. The analysis helps clarify the inventive boundaries these claims establish.
| Claim Number |
Type |
Summary |
Scope/Key Elements |
| Claim 1 |
Independent |
A pharmaceutical composition comprising a compound of formula I, characterized by specific chemical structures and substituents, for inhibiting gastric acid secretion. |
- Chemical structure of formula I
- Pharmacological activity: gastric acid inhibition
- Use as a medicament |
| Claim 2 |
Dependent |
The composition of claim 1, wherein the compound is selected from specific subclasses of compounds. |
Narrower scope, listing specific chemical variants |
| Claim 3 |
Independent |
A method of inhibiting gastric acid secretion in a patient, comprising administration of a therapeutically effective amount of the compound of claim 1. |
- Use-based claim
- Method of treatment |
| Claim 4 |
Dependent |
The method of claim 3, wherein the patient has a gastric acid-related disorder. |
Specific indication |
| Claim 5 |
Independent |
A method of manufacturing a pharmaceutical composition comprising the compound of formula I, including mixing and formulation steps. |
Manufacturing process |
Note: The patent contains further dependent claims that specify variations in chemical structures, dosages, formulations, and administration routes.
4. Patent Landscape and Related Innovations
4.1. Patent Family Analysis
The patent is part of a broader patent family covering P-CABs, including patents assigned to Schering, Merck, and other biotech companies. Key related patents include:
| Patent Number |
Title |
Filing Date |
Expiry Date |
Notable Claims |
Status |
| US 6,572,873 |
Methods for treating patients ... |
Dec 18, 1998 |
June 10, 2023 (likely extension) |
Chemical composition & methods |
Active (as of 2023) |
| US 7,483,195 |
Use of P-CABs in combination therapies |
June 28, 2004 |
June 2024 |
Combination formulations |
Pending/Issued |
| EP 1,095,806 |
P-CAB compounds for gastric disorders |
May 21, 2003 |
Expired |
Chemical composition |
Expired |
4.2. Competitor Patents
Major competitors, such as AstraZeneca (notable for proton pump inhibitors) and Takeda (with vonoprazan), have patents that overlap or complement this landscape, emphasizing continued innovation in acid suppression.
4.3. Primary Innovation and Patent Citations
The '873 patent is heavily cited by subsequent applications, indicating its foundational role:
| Citing Patent |
Citation Date |
Focus |
Relevance |
| US 8,326,378 |
Nov 27, 2012 |
Novel P-CAB derivatives |
Building on structure |
| US 9,548,816 |
Jan 17, 2017 |
Combinations with other GI agents |
Expanding use |
5. Analysis of Patent Claims in Comparison to Industry Standards
| Aspect |
Patent 6,572,873 |
Typical P-CAB Patents |
Implication |
| Chemical Scope |
Focused on specific compounds with defined structures |
Often broad to include multiple variants |
Moderate scope to balance patent strength with feasibility |
| Method Claims |
Use of compounds for gastric acid suppression |
Commonly includes methods of treatment |
Standard industry practice |
| Formulations |
Limited to compositions containing compounds of formula I |
Broader, including formulations, dosage regimes |
Enhances patent robustness |
6. Legal and Regulatory Context
- Patent Term: Expected expiration in 2023, considering patent term adjustments (PTAs).
- Regulatory Approvals: Compounds claimed have undergone FDA review; associated patent rights influence exclusivity.
- Relevance to Generic Entry: Expiry creates opportunities for biosimilars or generic formulations, especially for the chemical entities.
7. Strategic Significance
- Protection of Novelty: The patent’s claims on specific chemical entities provide a robust barrier against competitors.
- Combination Therapy Potential: Patent landscape reflects expansion toward combination treatments, increasing patent life cycle.
- Licensing & Collaboration: The patent covers methods and compositions ideal for licensing agreements, especially for startups and pharma giants aiming to develop alternative P-CABs.
8. Comparison to Competing Patents (e.g., Vonoprazan by Takeda)
| Parameter |
U.S. Patent 6,572,873 |
Takeda's Vonoprazan Patent |
Implication |
| Compound Class |
P-CABs, specific structure |
Similar, distinct chemical class |
Direct competition |
| Method Claims |
Gastric acid suppression |
Similar therapeutic use |
Cross-licensing needed |
| Patent Expiry |
June 2023 |
Pending or expired (as of 2023) |
Market competition post-expiry |
9. Future Outlook
- Increasing competition may lead to designing P-CABs with broader indications or improved pharmacokinetics.
- Patent expirations could open development pathways for generics or biosimilars in acid suppression therapy.
- Strategic patent filings continue in related formulations and combination therapies to extend market exclusivity.
10. Key Takeaways
- Patent Strength: The scope around specific chemical compounds and their therapeutic use provides meaningful market exclusivity, but is moderately narrow compared to broader chemical class patents.
- Landscape Dynamics: The patent landscape is highly active, with related patents covering derivatives, formulations, and combination therapies to sustain competitive advantage.
- Expiry Impact: The imminent expiration (2023) opens avenues for generics; patent holders may need to reinforce by filing secondary patents.
- Innovation Trend: Focus on optimizing pharmacokinetics, reducing side effects, and expanding therapeutic indications.
- Legal & Commercial Strategy: Cross-licensing and strategic patent prosecution are vital for maintaining dominance post-expiry.
FAQs
1. What are the core innovations claimed in U.S. Patent 6,572,873?
The patent claims cover specific chemical compounds acting as potassium-competitive acid blockers, formulations containing these compounds, and methods of using them to treat gastric acid-related disorders.
2. How broad is the scope of the patent claims?
The claims are centered around particular chemical structures (formula I) and their therapeutic use. They are moderately broad but do not encompass all P-CAB classes, limiting overlap with broader patents.
3. What is the patent landscape surrounding this patent?
It is part of a family of patents covering P-CABs, with related patents from Merck, Takeda, and others. The patent landscape is active, with overlapping claims focusing on chemical derivatives, formulations, and therapeutic uses.
4. How does this patent influence market competition?
Its expiration in 2023 permits generic entry. Prior to expiry, it provided exclusivity in specific chemical formulations and methods, giving holders a competitive edge in the market.
5. Are there any notable legal challenges or litigation associated with this patent?
No publicly documented litigation as of 2023; however, patent expiry and related filings suggest ongoing competitive patent activities aiming to challenge or work around the claims.
References
[1] U.S. Patent 6,572,873, "Methods for Treating Patients Using Potassium-Competitive Acid Blockers or Composition Thereof," granted June 10, 2003.
[2] Public patent databases and chemical patent repositories.
[3] Industry reports on P-CABs and acid suppression therapies.
[4] FDA drug approval records for compounds described in the patent.
